SARASOTA, Fla. (May 5, 2021) – Lumos Diagnostics announced today the expansion of its board with the appointment of three new independent directors to support the continued growth of the company’s rapid point-of-care diagnostic products and services business. Bronwyn Le Grice, Lawrence Mehren and Catherine Robson will join Executive Chair Sam Lanyon and Executive Director Rob Sambursky, MD.
“On behalf of the entire company, I am delighted to welcome Bronwyn, Larry and Catherine to the Lumos Board of Directors,” said Sam Lanyon, executive chair of Lumos Diagnostics. “Together, they offer extensive and diverse operational experience in growing diagnostic companies, strong knowledge of equity markets and broad corporate governance expertise. Lumos will benefit from their guidance as we expand our commercial infrastructure and global market access to novel point-of-care tests.”
Bronwyn Le Grice brings expertise in digital health and public market knowledge. She has more than eighteen years executive experience in the health technology sector including venture capital, corporate development and industry advocacy. In 2017, Ms. Le Grice founded ANDHealth, Australia’s only dedicated digital health accelerator and commercialization support organization.
Lawrence Mehren provides diagnostic operational proficiency and public market experience. He served as the Chief Executive Officer and a Director of Accelerate Diagnostics (Nasdaq AXDX) from 2012 to 2020. Before this, Mr. Mehren served as Senior Vice President and Chief Financial Officer of Ventana Medical Systems, Inc. from 2007 until 2008 and as Head of Global Business from 2008 until 2011.
Catherine Robson expands Lumos’ financial capabilities and corporate governance experience. Catherine founded Affinity Private Advisors, a financial services firm and has non-executive director experience at Greater Bank, SCALE Investors and on ASX-listed Equity Trustees (EQT Holdings Limited), where she is the chair of the Risk Committee and member of the Audit and Remuneration, Human Resources and Nominations Committees.
Lumos Board Executive Chair Sam Lanyon has more than twenty-five years of experience in business strategy, executive sales and operational management with a demonstrated track record in the global commercialization of technology rich healthcare products. He also serves as Co-CEO and co-founder of Planet Innovation.
Executive Director Rob Sambursky, MD, is one of the original founders and former executives of RPS Diagnostics, which merged with Lumos Diagnostics in 2019, and currently leads Lumos as its President and Chief Executive Officer. In addition to his product development and commercial experience, he has a strong scientific and clinical background in medical sciences, ophthalmology and infectious disease.
About Lumos Diagnostics
Lumos Diagnostics specializes in rapid, cost-effective and complete point-of-care (POC) diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercializes novel, Lumos-branded POC tests that target infectious and inflammatory diseases with unmet diagnostic needs.
Lumos has been admitted to the Australian Securities Exchange (ASX) with trading commencing on July 5, 2021 after raising $63 million AUD in an Initial Public Offering (IPO).